CLDX - Latest News
Celldex Therapeutics, Inc. (CLDX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.16B. Beta to the broader market is 0.98.
The article list below shows the most recent CLDX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CLDX Headlines
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
zacks.com - May 7, 2026
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1. 18 per share versus the Zacks Consensus Estimate of a loss of $1.
Celldex Reports First Quarter Financial Results and Provides Corporate Update
globenewswire.com - May 7, 2026
HAMPTON, N. J.
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
seekingalpha.com - May 7, 2026
Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's rob
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
zacks.com - May 4, 2026
The mean of analysts' price targets for Celldex (CLDX) points to a 76. 4% upside in the stock.
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
defenseworld.net - Apr 15, 2026
Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H. C.
How News Affects CLDX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CLDX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CLDX news questions
- What is the latest CLDX news headline?
- The most recent CLDX headline (May 7, 2026) is "Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CLDX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CLDX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CLDX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.